RESEARCH ARTICLE

Assessment of Corneal Sensation, Innervation and Retinal Nerve Fiber Layer in Patients Treated with Multiple Intravitreal Ranibizumab Injections

Gulfidan Bitirgen1*, Selman Belviranli1, Rayaz A. Malik2, Hurkan Kerimoglu1, Gunhal Satirtav1, Nazmi Zengin1

1 Department of Ophthalmology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey, 2 Weill Cornell Medicine-Qatar, Education City, Doha, Qatar & Central Manchester University Teaching Hospitals Foundation Trust and Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom

* gbitirgen@yahoo.com

Abstract

Purpose
To evaluate the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (AMD).

Methods
Sixty-six eyes of 33 patients who had received unilateral repeated intravitreal ranibizumab injections (0.5 mg/0.05 ml) for the treatment of AMD and 25 eyes of 25 healthy subjects were included in the study. Central corneal sensation was measured using the contact Cochet-Bonnet esthesiometer. The laser scanning in vivo corneal confocal microscope was used to determine corneal SBNP parameters. The peripapillary RNFL thickness was assessed with spectral-domain optical coherence tomography. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow non-treated eyes and the eyes of healthy control subjects.

Results
The mean number of ranibizumab injections per eye was 8.9±5.0 (range 3–20). There were no statistically significant differences in the central corneal sensitivity threshold and corneal SBNP parameters between the ranibizumab-injected eyes and the fellow untreated eyes or between those with neovascular AMD and the healthy control group (P>0.05 for all). The average peripapillary RNFL thickness of the treated eyes did not differ significantly to the fellow eyes (P = 0.237), and the eyes of healthy control subjects (P = 0.918). There were no significant correlations between the number of ranibizumab injections and any of the study parameters.
Conclusions

Multiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD.

Introduction

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among elderly people in developed countries [1]. Neovascular or exudative AMD, characterized by new formation of choroidal vessels into the sub-retinal space, is responsible for almost 90% of severe vision loss due to AMD [2]. Although the age-related changes that stimulate pathologic neovascularization are not completely understood, vascular endothelial growth factor A (VEGF-A), which is a key regulator of angiogenesis and vascular permeability, has been implicated as an important factor in the pathogenesis of AMD [3,4].

Ranibizumab, a recombinant humanized monoclonal antibody antigen-binding fragment that neutralizes all known active forms of VEGF-A, has widely been used via intravitreal injection for the treatment of neovascular AMD [5]. However, the effect of VEGF is not limited to angiogenesis and vascular permeability. Reassuringly a recent study has shown no effect on corneal endothelial cell density or morphology after intravitreal bevacizumab or ranibizumab in patients with diabetic macular edema [6]. However, experimental studies have documented that VEGF is expressed by neurons mediating neuroprotective and neurotrophic activities [7–9], and neutralization of VEGF, using anti-VEGF antibodies impairs regeneration of the corneal sub-basal nerve plexus (SBNP) in injured mice corneas [10]. Repeated intravitreal injections of ranibizumab might therefore induce a detrimental effect on the corneal SBNP and retinal nerve fiber layer (RNFL). Several studies have investigated the effects of anti-VEGF on RNFL, reporting either decreased, increased or unchanged RNFL thickness in the eye treated with intravitreal anti-VEGF agents [11–15]. To our knowledge, there are no data in the current literature regarding the effects of intravitreal anti-VEGF agents on the human corneal SBNP.

In this study, we evaluated the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal SBNP morphology and peripapillary RNFL thickness in patients with neovascular AMD.

Materials and Methods

Thirty-three patients (16 male, 17 female) with unilateral neovascular AMD who had received at least three injections of intravitreal ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) and 25 healthy control subjects (14 male, 11 female) were enrolled in this cross-sectional study undertaken at a tertiary referral center. The study design fulfilled the tenets of the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of the Necmettin Erbakan University. Written informed consent was obtained from all patients after a detailed explanation of the nature and possible consequences of the study.

Medical records of all patients were reviewed for age, gender, pre-existing glaucoma, use of anti-glaucomatous medications and clinical examination findings. The total number of intravitreal injections and the time elapsed from the last injection were also recorded. The patients had received initially three monthly intravitreal ranibizumab (0.5 mg/0.05 ml) injections.
Afterward, re-injections had been performed according to an “as needed” protocol based on the PrONTO trial [16]. None of the patients experienced systemic or ocular complications including intraocular inflammation, endophthalmitis, or thromboembolic events. Patients were excluded if they had a history of glaucoma, elevated intraocular pressure (IOP) during follow-up, trauma or ophthalmic surgery, any corneal pathology and coexisting retinal or neuro-ophthalmologic diseases. Patients with systemic diseases other than controlled hypertension were also considered ineligible.

All patients underwent a complete ophthalmologic evaluation, including anterior segment biomicroscopy, IOP assessment and fundus examination. The patients with neovascular AMD were included if the fellow eye was without AMD findings or just early dry AMD. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow eyes. Since the intravitreal administration of ranibizumab may affect the fellow eyes of the patients via the systemic circulation, 25 eyes of 25 healthy subjects were also included.

Central corneal sensation was measured before the IOP assessment, using a contact nylon thread esthesiometer (Luneau 12/100 mm Cochet-Bonnet; Luneau, Prunay le Gillon, France). The nylon filament, which mechanically stimulates corneal nerves, was applied with a low pressure perpendicularly to the center of the cornea. Starting from 6 cm, the filament length was progressively reduced in 5-mm steps until the first response occurred. The longest filament length (cm) resulting in a positive response was verified twice and recorded as the indicator of the central corneal sensitivity [17].

The laser scanning in vivo corneal confocal microscopy (IVCCM) was performed on all subjects using the Rostock Corneal Module/Heidelberg Retina Tomograph III (RCM/HRT III; Heidelberg Engineering GmBH, Dossenheim, Germany). The full thickness of the central cornea was scanned by using the device’s “section” mode. The total duration of IVCCM examination was approximately 2 minutes per eye, and none of the subjects experienced any visual symptoms or corneal complications as a result of examination. The best-focused SBNP images were considered for the analysis. Automatic CCMetrics software, ver. 2.0 (University of Manchester, UK) was used for the quantitative analysis of the nerve fibers [18]. Three parameters were quantified: corneal nerve fiber density (NFD), the total number of major nerves per square millimeter; nerve fiber length (NFL), the total length of all nerve fibers and branches (millimeters per square millimeter); and nerve branch density (NBD), the number of branches emanating from major nerve trunks per square millimeter [19]. All of the image analyses were performed by a single masked observer.

The peripapillary RNFL thickness measurements were obtained using a spectral-domain optical coherence tomography (OCT) (Heidelberg Engineering, Heidelberg, Germany). The OCT scanning circle (size: 3.4 mm) was manually positioned at the center of the optic disc and the average peripapillary RNFL thickness (μm) was recorded.

Statistical analysis was performed using SPSS ver. 17.0 (Chicago, IL, USA) software. Basic descriptive statistics were calculated on all the data gathered and are reported as the mean±SD or n (%), as appropriate. The Pearson χ² test was used to compare the categorical parameters. Normal distribution of continuous variables was confirmed with the Shapiro-Wilk test. Paired samples t-test or Wilcoxon signed ranks tets was used to compare the parameters between the ranibizumab-injected eyes and fellow eyes. Independent samples t-test or Mann-Whitney test was used to compare the parameters between the ranibizumab-injected eyes and the eyes of healthy control subjects. The correlations between the number of injections and corneal sensitivity threshold, peripapillary RNFL thickness and corneal SBNP parameters were measured by using Pearson’s correlation coefficient. For all evaluations, a P value of less than 0.05 was considered statistically significant.
Results

The mean ages of the patients and control group were 67.91±7.29 years (range 55–81 years) and 66.24±7.24 years (range 56–85 years), respectively. There were no statistically significant differences between patients with AMD and healthy controls for age (P = 0.391) and gender (P = 0.571). No significant differences were observed in central corneal sensitivity threshold, corneal SBNP parameters and peripapillary RNFL thickness between male and female genders in both the AMD and control groups (P>0.05 for all). The mean number of injections was 8.9±5.0 (range 3–20) and the mean time elapsed from the last intravitreal injection treatment was 2.7±1.7 months (range 1–6 months). The mean IOP of eyes receiving ranibizumab injections (14.79±2.58 mmHg) did not differ significantly from those of the fellow eyes (14.73±2.75 mmHg) and control eyes (13.56±2.66 mmHg) (P = 0.837 and P = 0.082, respectively).

Table 1 shows the comparison of central corneal sensitivity threshold, corneal SBNP parameters and peripapillary RNFL thickness among ranibizumab-injected eyes and fellow eyes of the patients with AMD and the healthy control group. Representative IVCCM images of the central cornea showing the SBNP in a patient with neovascular AMD and a healthy control subject are given in Fig 1. There were no statistically significant differences between the ranibizumab-injected eyes and fellow eyes, as well as the ranibizumab-injected eyes and control eyes (P>0.05 for all). In order to detect any early changes on corneal nerves, the results of a subgroup including 12 patients who had received ranibizumab one month prior to the examination were analysed separately and no significant differences were observed in any of the study parameters between the ranibizumab-injected eyes and fellow eyes (The average values of the parameters for the ranibizumab-injected eyes and fellow eyes are as follows: 5.63 ± 0.57 vs. 5.75 ± 0.34 for the central corneal sensation, 24.48 ± 11.45 vs. 29.16 ± 10.44 for NFD, 33.33 ± 19.27 vs. 36.97 ± 11.95 for NBD, 16.49 ± 3.42 vs. 16.52 ± 4.41 for NFL, and 94.83 ± 6.60 vs. 89.92 ± 12.23 for the RNFL thickness; P>0.05 for all).

Among the 33 patients with AMD, 11 (33.3%) had treated and controlled hypertension. There were no significant differences in any of the study parameters between patients with and without hypertension (P>0.05 for all).

Table 1. Comparison of the study parameters in ranibizumab-injected eyes and fellow eyes of patients with neovascular age-related macular degeneration and the eyes of healthy control subjects.

|                        | Ranibizumab-injected Eye (n = 33) | Fellow Eye (n = 33) | Control (n = 25) | Ranibizumab vs. Fellow P value | Ranibizumab vs. Control P value |
|------------------------|----------------------------------|--------------------|------------------|--------------------------------|-------------------------------|
| Central corneal sensation (mm) | 5.72 ± 0.39                     | 5.77 ± 0.31        | 5.82 ± 0.28      | 0.617a                          | 0.336b                        |
| NFD (fibers/mm²)        | 27.46 ± 10.23                    | 28.40 ± 9.12       | 29.74 ± 8.12     | 0.669c                          | 0.362d                        |
| NBD (branches/mm²)      | 38.06 ± 17.70                    | 40.52 ± 16.32      | 45.24 ± 19.45    | 0.482c                          | 0.148d                        |
| NFL (mm/mm²)            | 16.30 ± 3.88                     | 16.96 ± 3.95       | 17.45 ± 3.11     | 0.336c                          | 0.231d                        |
| Average RNFL thickness (µm) | 95.52 ± 10.10                    | 93.55 ± 11.43      | 95.84 ± 13.75    | 0.237c                          | 0.918d                        |

a Wilcoxon signed ranks test.
b Mann-Whitney test.
c Paired samples t-test.
d Independent samples t-test.

Data are the mean ± SD. NBD, nerve branch density; NFD, nerve fiber density; NFL, nerve fiber length; RNFL, retinal nerve fiber layer.

doi:10.1371/journal.pone.0170271.t001
No significant correlations were observed between the number of ranibizumab injections and any of the study parameters (\(P > 0.05\) for all). There was a significant positive correlation between central corneal sensitivity threshold and NFD (\(r = 0.362; P = 0.005\)).

**Discussion**

The use of intravitreal injections of anti-VEGF agents for the treatment of retinal diseases, especially neovascular AMD, is now common practice. We found no significant change in corneal sensation or corneal nerve and retinal nerve fiber morphology in ranibizumab-injected eyes. This is reassuring given the theoretical concern of a potentially detrimental effect on nerves in the eye following anti-VEGF therapy, given that endogenous VEGF has neurotrophic and neuroprotective effects [20]. Indeed, Matsuzaki et al [21]. have demonstrated direct protective effects of VEGF-A on cultured neuronal cells. It has also been shown that a chronic decrease in endogenous VEGF-A levels is linked to an increased risk of motor neuron degeneration in amyotrophic lateral sclerosis [22]. In a more recent study, Hulse et al [23]. reported that VEGF-A165b, which is a splice isoform of VEGF-A, had neuroprotective and anti-nociceptive effects on epidermal sensory neurons in diabetic rats. In relation to neural changes there are experimental data showing the neuroprotective role of VEGF on retinal neural cells [8,24].

The role of VEGF on corneal innervation and nerve repair has also been investigated. Yu et al [10]. have shown a significant effect of VEGF on the growth of peripheral trigeminal neurons innervating the cornea in mice and suggested that blockage of VEGF signaling impairs regeneration of the corneal sub-basal nerve plexus after injury. Similarly, another recent study has demonstrated the neuroregenerative role of VEGF on corneal nerves using an avascular corneal nerve injury model [25]. These experiments provide support for the critical impact of VEGF on corneal and retinal neural cells and the potential for harm to ocular neural tissue in patients undergoing chronic anti-VEGF treatment. This provides the rationale for assessing the effect of ranibizumab on corneal nerves and peripapillary RNFL in patients with neovascular AMD.

Many studies have assessed the effects of anti-VEGF agents on the RNFL [11,13–15,26]. Theoretically, RNFL alterations could be induced by the IOP elevation in response to volume increase or through a direct neurotoxic effect of the drug. A short-term transient IOP rise occurs with intravitreal drug administration, but is limited to the first few minutes following injection and returns to baseline within 30–60 minutes [27,28]. We have not measured the IOP immediately after the injection and therefore cannot assess the contribution of this
temporary rise in IOP to any effect on RNFL thickness. Although Martinez-de-la-Casa et al [11]. have demonstrated a significant decrease in RNFL thickness in 49 patients with neovascular AMD treated with a mean number of 4.8 ranibizumab injections, the majority of researchers have shown that repeated intravitreal injections of anti-VEGF agents are not associated with a change in RNFL [13–15,26]. Similarly in this study, we have also not observed any significant correlation between the number of injections and RNFL thickness.

Although several studies have investigated the effects of anti-VEGF on RNFL, no prior study has addressed the possible effects of intravitreal anti-VEGF agents on the corneal SBNP. Pharmacokinetic studies have shown that ranibizumab concentration peaks in aqueous humor 1–3 days after intravitreal injection and subsequently declines with a half life of 2.84 days in rabbits [29] and 7.19 days in human [30]. In an experimental study by Dratviman-Storobinsky et al [31], immunostaining showed bevacizumab in the anterior chamber and corneal stroma one day after intravitreal injection, suggesting that bevacizumab had reached the corneal stroma by passive diffusion via the endothelium. Since ranibizumab is a smaller molecule than bevacizumab, it is possible that ranibizumab may also reach the corneal stroma and have a deleterious effect on corneal nerves. To the best of our knowledge, this is the first study to investigate the morphology and function of corneal SBNP after repeated intravitreal injections of ranibizumab. We find no significant change in corneal sensation or corneal nerve morphology in ranibizumab-injected eyes. A limitation of this study is that the preinjection evaluations have not been performed due to the cross-sectional nature of the study. Further prospective studies with larger numbers of subjects including pseudophakic, aphakic, or vitrectomized eyes are recommended to fully evaluate the potential harmful effects of intravitreal injections of anti-VEGF agents.

In animal studies, the aqueous humor concentrations of ranibizumab in the non-injected fellow eye have found to be below the limit of detection and aqueous humor VEGF concentrations of the fellow eye remain unchanged following intravitreal injection [29,32]. Additionally, Gamulescu and Helbig [33] have reported no contralateral eye effect in a short-term prospective study of 26 patients with bilateral neovascular AMD who had received ranibizumab injection in one eye. Although Rouvas et al [34]. observed a positive impact of ranibizumab on the visual acuity of the fellow eye in patients with bilateral AMD. Given that a single intravitreal administration of 0.5 mg of ranibizumab in monkeys results in a maximum serum concentration of 150 ng/ml [35], a systemic effect on the contralateral eye should also be accounted for. Therefore a healthy control group was also included in the present study. No significant differences were observed between ranibizumab-injected eyes and the eyes of healthy controls for any of the parameters.

In conclusion, repeated treatment with intravitreal ranibizumab has no adverse effects on corneal sensation, corneal SBNP morphology and peripapillary RNFL thickness.

Author Contributions

Conceptualization: GB RAM HK.
Data curation: GB SB HK.
Formal analysis: GB RAM HK.
Funding acquisition: GB HK GS.
Investigation: GB SB GS.
Methodology: GB SB GS NZ.
Project administration: GB RAM HK GS.

Resources: GB HK GS.

Supervision: RAM NZ.

Validation: RAM NZ.

Writing – original draft: GB SB.

Writing – review & editing: RAM NZ.

References
1. Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004; 122: 477–485. doi: 10.1001/archopht.122.4.477 PMID: 15078664
2. Ferris FL 3rd, Fine SL, Hauser SL. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102: 1640–1642. PMID: 6208888
3. Kvanta A, AlGVærin P, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996; 37: 1929–1934. PMID: 8759385
4. Kliffen M, Sharma HS, Moon CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997; 81: 154–162. PMID: 9059252
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al; MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419–1431. doi: 10.1056/NEJMoa054481 PMID: 17021318
6. Guzel H, Bakbak B, Koylu MT, Gonul S, Ozturk B, Gedik S. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema. Cutan Ocul Toxicol. 2016.
7. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci. 1999; 19: 5731–5740. PMID: 10407014
8. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007; 171: 53–67. doi: 10.2353/ajpath.2007.061237 PMID: 17591953
9. Li Z, Burns AR, Han L, Rumbaut RE, Smith CW. IL-17 and VEGF are necessary for efficient corneal nerve regeneration. Am J Pathol. 2011; 178: 1106–1116. doi: 10.1016/j.ajpath.2010.12.001 PMID: 21358362
10. Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci. 2008; 49: 3870–3878. doi: 10.1167/iovs.07-1418 PMID: 18487369
11. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012; 53: 6214–6218. doi: 10.1167/iovs.12-9875 PMID: 22915037
12. Yau GL, Campbell RJ, Li C, Sharma S. Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration. Can J Ophthalmol. 2015; 50: 345–349. doi: 10.1016/j.cjo.2015.01.008 PMID: 26455968
13. Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Ophthal Mo. 2010; 150: 558–561. doi: 10.1016/j.ajo.2010.04.029 PMID: 20643396
14. Shin HJ, Shin KC, Chung H, Kim HC. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal anti-vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014; 55: 2403–2411. doi: 10.1167/iovs.13-13769 PMID: 24609624
15. Sobacı G, Güngör R, Ozge G. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol. 2013; 6: 211–215. doi: 10.3980/j.issn.2222-3959.2013.02.20 PMID: 23638426
16. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michaels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148: 43–58. doi: 10.1016/j.ajo.2009.01.024 PMID: 19376495

17. Xu KP, Yagi Y, Tsubota K. Decrease in corneal sensitivity and change in tear function in dry eye. Cornea 1996; 15: 235–239. PMID: 8713924

18. Dabbah MA, Graham J, Petropoulos IN, Tavakoli M, Malik RA. Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging. Med Image Anal. 2011; 15: 738–747. doi: 10.1016/j.media.2011.05.016 PMID: 21719344

19. Malik RA, Kallikinos P, Abbott CA, van Schie CH, Morgan P, Efron N, et al. Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003; 46: 683–688. doi: 10.1007/s00125-003-1086-8 PMID: 12739016

20. Zachary I. Neuroprotective role of vascular endothelial growth factor: signaling mechanisms, biologic function, and therapeutic potential. Neurosignals 2005; 14: 207–221. doi: 10.1159/000088637 PMID: 16301836

21. Matsuzaki H, Tamatani M, Yagamuchi A, Namikawa K, Kiyama H, Vitek MP, et al. Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J. 2001; 15: 1124–1200. PMID: 11344093

22. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003; 34: 383–394. doi: 10.1038/ng1211 PMID: 12847526

23. Hulse RP, Beazley-Long N, Ved N, Bestall SM, Riaz H, Singhal P, et al. Vascular endothelial growth factor-A165b prevents diabetic neuropathic pain and sensory neuronal degeneration. Clinical Science 2015; 129: 741–756. doi: 10.1042/CS20150124 PMID: 26201024

24. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008; 3: e3554. doi: 10.1371/journal.pone.0003554 PMID: 18978936

25. Pan Z, Fukuoka S, Karagianni N, Guaiquil VH, Rosenblatt MI. Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea. FASEB J. 2013; 27: 2756–2767. doi: 10.1096/fj.12-225185 PMID: 23568776

26. El-Ashry MF, Lascaratos G, Dhillon B. Evaluation of the effect of intravitreal ranibizumab injections in patients with neovascular age related macular degeneration on retinal nerve fiber layer thickness using optical coherence tomography. Clin Ophthalmol. 2015; 9: 1269–1274. doi: 10.2147/OP TH.S80704 PMID: 26203216

27. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146: 930–934. doi: 10.1016/j.ajo.2008.07.007 PMID: 18775528

28. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007; 42: 807–811. doi: 10.1016/j.cjo.2007.07.012 PMID: 18026202

29. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179–2182. doi: 10.1016/j.ophtha.2007.09.012 PMID: 18054637

30. Krohe TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012; 154: 682–686. doi: 10.1016/j.ajo.2012.03.047 PMID: 22818800

31. Dratviman-Storobinisky O, Lubin BC, Hasanreisoglu M, Goldberg-Cohen N. Effect of subconjunctival and intravitreal bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis. 2009; 15: 2326–2338. PMID: 19936307

32. Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: Intraocular pharmacokinetics and their effects on aqueous vegf level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci. 2015; 56: 6501–6505. doi: 10.1167/iovs.15-17279 PMID: 26447985

33. Gamulescu MA, Helbig H. Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther. 2010; 26: 213–216. doi: 10.1089/jop.2009.0126 PMID: 20415626

34. Rouvas A, Liarakos VS, Theodossiadis P, Papatheoasiou S, Petrou P, Ladás I, et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 2009; 223: 383–389. doi: 10.1159/000228590 PMID: 19602910

35. Gaudreau J, Fei D, Rusil J, Suboc P, Shiù V. Preclinical pharmacokinetics of ranibizumab (rhUFabv2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46: 726–733. doi: 10.1167/ iovs.04-0601 PMID: 15671306